COMBINATION OF TRIFLURIDINE/TIPIRACIL HYDROCHLORIDE, ANTITUMOR PLATINUM COMPLEX, AND MODULATOR OF CONTROL POINTS OF IMMUNE RESPONSE Russian patent published in 2022 - IPC A61K31/282 A61K31/513 A61K31/7072 A61K39/395 A61P35/00 

Abstract RU 2778887 C2

FIELD: medicine.

SUBSTANCE: group of inventions relates to the field of medicine, namely to a combination intended for the use in the treatment of colon and rectum cancer or gastrointestinal tract cancer, containing: a drug trifluridine-tipiracil hydrochloride (hereinafter – FTD-TPI), an antitumor platinum complex, which is oxaliplatin, and a modulator of control points of an immune response, which is nivolumab. The invention also relates to a drug intended for the use in the treatment of colon and rectum cancer or gastrointestinal tract cancer, containing, separately or together: a drug FTD-TPI, an antitumor platinum complex, which is oxaliplatin, and a modulator of control points of an immune response, which is nivolumab, intended for simultaneous or sequential use, where each component is provided in effective amount for the treatment of cancer.

EFFECT: group of inventions provides for the development of a new method for the treatment of gastrointestinal tract cancer.

18 cl, 6 dwg

Similar patents RU2778887C2

Title Year Author Number
ANTICANCER AGENT AND METHOD FOR PREDICTION OF THERAPEUTIC EFFECT FOR PATIENTS WITH COLON CANCER AND RECTUM GENE MUTATION KRAS 2012
  • Ito Masanobu
  • Okabe Khiroyuki
RU2585528C2
ANTITUMOR AGENT CONTAINING IMMUNOMODULATOR AND ANTITUMOR EFFECT ENHANCER 2017
  • Suzuki, Norihiko
RU2747480C2
IMMUNE RESPONSE PRESERVATION DURING CHEMOTHERAPEUTICAL SHEMES 2017
  • Sorrentino, Jessica A.
  • Lai, Anne Y.
  • Strum, Jay C.
  • Roberts, Patrick, Joseph
RU2779478C2
ANTITUMOUR DRUG CONTAINING ANTITUMOUR PLATINUM COMPLEX, AND ANTITUMOUR EFFECT ENHANCER 2015
  • Okabe, Hiroyuki
RU2678103C2
ANTICANCER MEDICINE, CONTAINING α,α,α-TRIFLUOROTHYMIDINE AND THYMIDINE PHOSPHORYLASE INHIBITOR 2006
  • Emura Tomokhiro
  • Mita Akira
RU2394581C2
ANTITUMOUR AGENT AND ANTITUMOUR EFFECT ENHANCER 2014
  • Okabe Khiroyuki
RU2682161C2
METHOD FOR PREDICTING THERAPEUTIC EFFECT FOR PATIENT WITH COLORECTAL CANCER WITH INCREASED TK1 PROTEIN EXPRESSION 2014
  • Sakamoto, Kazuki
  • Ito, Masanobu
RU2677656C2
ANTITUMOR AGENT AND ANTITUMOR EFFECT AMPLIFIER 2018
  • Haruma Tomonori
RU2783759C2
ANTITUMOUR AGENT INCLUDING IRINOTECAN HYDROCHLORIDE HYDRATE 2014
  • Okabe Khiroyuki
RU2657604C2
CONTROL POINT INHIBITOR AND WHOLE MYCOBACTERIAL CELLS FOR USE IN CANCER THERAPY 2016
  • Akle Charles
  • Brunet Laura Rosa
RU2733033C2

RU 2 778 887 C2

Authors

Abastado Jean-Pierre

Amellal Nadia

Bruno Alain

Burbridge Michael Frank

Cattan Valerie

Leger Catherine

Dates

2022-08-29Published

2018-03-16Filed